CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project

SUZHOU, China, March 2, 2021 /PRNewswire/ — CMAB Biopharma (Suzhou) Inc (“CMAB”) congratulates its partner Innovent Biologics, Inc (“Innovent”) (1801.HK) on the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate which targets the COVID-19 virus, an independently-developed project by Innovent. Utilizing its state of the art facility and robust quality systems, CMAB provided integrated CDMO services for this program from cell bank construction to cGMP production of drug substance at the 2,000 L upstream scale.

“It has been our great pleasure to have this opportunity to collaborate with a preeminent organization like Innovent on such a critical product, and be able to contribute to its projects meanwhile”, said Dr. Yongzhong Wang, CEO of CMAB, “Throughout the project, the two organizations worked collaboratively together to successfully complete the CMC activities efficiently, rapidly and according to international regulatory standards. Both organizations are very proud of this accomplishment and CMAB looks forward to continuing provide high-quality and fast CDMO services to Innovent and other biopharmaceutical companies in the future.”

About CMAB Biopharma (Suzhou), Inc.

CMAB is a flexible full-service CDMO dedicated to providing bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. CMAB complies with global quality standards, we get European commission EudraLex (EMA) Vol 4. GMP guidelines which is a successful external QP Audit by Parexel.

To find out more about our dynamic CDMO, please go to the website: www.cmabbio.com  

CMAB Biopharma (Suzhou) Inc
Address: C37&C29, No.188 Dongping Street, Suzhou Industrial Park
Tel: 0512-6799 5177
Business Contact: [email protected]
Public Relations: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/cmab-biopharma-congratulates-partner-innovent-biologics-on-fda-clearance-of-ind-application-of-its-covid-19-antibody-project-301239181.html

SOURCE CMAB Biopharma (Suzhou) Inc

CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project WeeklyReviewer

PR Newswire Science News

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

WeeklyReviewer earns commissions through affiliates of qualifying products through Amazon Associates, Fiverr Affiliates, Hostgator Affiliates, Namecheap Affiliates, NordVPN Affiliates, Semrush Affiliates, Alibaba Affiliates, Clickfunnels Affiliate, Leadpages Affiliates, Cryptohopper Affiliates, Binance Affiliates and more.

Clicking on links in WeeklyReviewer may or may not provide us commission through any qualifying purchases.

CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project WeeklyReviewer
World Reviewer Staffhttps://weeklyreviewer.com/
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Related articles

WeeklyReviewer